about
Genetic, immunological, and pharmacological strategies to generate improved oncolytic virusesTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyTrial Watch:: Oncolytic viruses for cancer therapyTrial watch: Dendritic cell-based anticancer therapyTrial Watch-Oncolytic viruses and cancer therapyTrial Watch: Peptide-based anticancer vaccines.First oncolytic virus approved for melanoma immunotherapy.HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccinesMaraba virus as a potent oncolytic vaccine vector.Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination.Customized Viral Immunotherapy for HPV-Associated Cancer.S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3.Fasting improves anticancer immunosurveillance via autophagy induction in malignant cells.Autophagy induction for the treatment of cancerAlternative splicing-regulated protein of hepatitis B virus hacks the TNF-α-stimulated signaling pathways and limits the extent of liver inflammation.Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses.Trial Watch: DNA vaccines for cancer therapy.Consensus guidelines for the detection of immunogenic cell death.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Panorama from the oncolytic virotherapy summit.Trial Watch: Radioimmunotherapy for oncological indications.Prospective comparison of Abbott RealTime HBV DNA and Versant HBV DNA 3.0 assays for hepatitis B DNA quantitation: impact on HBV genotype monitoring.Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease.Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance.Metabolic effects of fasting on human and mouse blood in vivo.Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy.Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapiesTrial watch: DNA-based vaccines for oncological indicationsHDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss VariantsTrial watch: peptide-based vaccines in anticancer therapyImpact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohortsPreclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trialsMetabolic vulnerability of cisplatin-resistant cancersAnticancer effects of anti-CD47 immunotherapy in vivoCrizotinib-induced immunogenic cell death in non-small cell lung cancer
P50
Q26859879-F89D758F-4DE8-472D-8862-B4D994C6608DQ27004011-9DBF0AEF-D742-4AB5-9A77-99859EAA6784Q27021951-EAFCEACD-9A02-4898-B27F-2F9A6EC2389BQ27024047-BB7B4F1A-26BF-4363-A174-6CCA7A8EE40EQ28072347-0A5EDF53-EC97-4F2D-8E0B-49ED5577C36FQ34483345-C2EA799A-304F-439A-9FE6-5A94FCD70B0AQ36597333-717FBFA6-CB5A-4054-BE73-DA75E71A2FCFQ36740297-421F1577-1628-47BC-A5C5-AA8F18611E64Q37196054-8337AD48-67F8-4051-B7FF-1D48241B75D7Q37562080-2E19CF1F-6A2A-404E-A4EE-3C19B10B5CA2Q38648891-CAE883DC-AB66-4334-91E0-1689B97B38CAQ38758370-5B9EEB6B-9C21-432D-B239-875FAC179FFDQ39000548-AC3B7CF4-62FD-419D-B66F-E75555783813Q39763165-6BA60CD4-C1AB-41A2-96E6-B8F33F6311D1Q40040094-DD338880-23E5-45FF-8403-A15ABA8D23BDQ40729421-38EEC2F1-E70D-4625-BFD1-554572393A41Q41144675-6ECC1A59-97B3-4110-A068-53C88E446DE4Q41574754-3D136D7D-9988-4D53-9FA5-D3E5FC03D172Q42173391-A2CCCF0B-750A-43A1-9767-95BD39C0FE54Q42278488-EF9A8076-AC3D-4DF4-978F-A750287CF733Q42552005-114F3E28-EF36-4AA7-8C2B-A8079D1ACD45Q42553556-37F2F0BA-CE64-4262-B90F-7573DA5F64CFQ42558833-63F5B3FB-0802-42F7-9318-4B5D5F99A687Q42934744-3A4C0184-CD93-461D-8863-C105AA86EB79Q43104064-60700E8C-00DB-429E-B861-FD3F0DA42EFEQ44813770-61F28952-1C69-4126-B975-E864A1C223CBQ44849257-E5B2DAF3-A373-4662-BAB0-BF4E61343520Q47560736-C0CD5727-497D-4F45-AA3F-F60D7B756C7EQ48193651-BEB0FAC2-1014-49F6-8655-457A9D5B61F5Q49970544-27EADC66-9ED6-4A4C-992D-693839538D7AQ52581847-4767C915-D4AD-467E-8CBF-58E7BF6DA7B4Q56892795-E7E6F551-811C-44AE-979A-8771314CDE0DQ56893452-FA9998C5-A029-41E8-ABD8-F83F5E4C1B42Q56980315-52DC023D-1FB3-4A3C-9EE9-1AC6CDD0042BQ57082680-E0BCE574-18DA-45CC-9DC4-626824DF734EQ57082684-79160B8A-3ADB-46CB-B640-B6EC73137E25Q58416976-103EE873-2BB0-4AC8-998E-63F58E0DC60EQ58416980-F4476B62-482B-4CF9-A9F6-D49BC3514AB3Q60395214-F4ADBD0E-BCE2-4C66-8B7D-E2AC4CDD894CQ64086405-2AC2CA2E-A453-4D23-BE16-F827F3202853
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jonathan G Pol
@ast
Jonathan G Pol
@en
Jonathan G Pol
@es
Jonathan G Pol
@nl
Jonathan G Pol
@sl
type
label
Jonathan G Pol
@ast
Jonathan G Pol
@en
Jonathan G Pol
@es
Jonathan G Pol
@nl
Jonathan G Pol
@sl
prefLabel
Jonathan G Pol
@ast
Jonathan G Pol
@en
Jonathan G Pol
@es
Jonathan G Pol
@nl
Jonathan G Pol
@sl
P106
P21
P31
P496
0000-0002-8355-7562